510(k) device
cobas BKV
Roche Molecular Systems, Inc. · Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX, Class II) · First FDA decision Jan 29, 2021, newest Jan 29, 2021Kidney failure and dialysis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "cobas BKV"
MAUDE reports
0
Brand "cobas BKV", since 2015
PubMed studies
3
Mentioning "cobas BKV"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing cobas BKV
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- cobas BKV510(k)
K203220 · Decided Jan 29, 2021 · 88 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38227First Coast Service Options, Inc.Updated Oct 20, 2023
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38229Novitas Solutions, Inc.Updated Oct 20, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "cobas BKV", any status and sponsor, newest update first.
No registered device study names "cobas BKV".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "cobas BKV", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QLX
8 reports: 8 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "cobas BKV"[tiab]. The summary above synthesizes these.
- Performance of the cobas EBV and cobas BKV assays: multi-site comparison of standardized quantitation.
Mannonen L, Jokela P, Kragh Thomsen M, et al. · J Clin Microbiol · 2024Comparative Study, Multicenter Study
- Performance evaluation of the high-throughput quantitative Alinity m BK virus assay.
Hirschhorn JW, Sasaki MM, Kegl A, et al. · J Clin Microbiol · 2024
- Stability of BK polyomavirus DNA in urine over time and analytical evaluation of an automated BKV quantitative nucleic acid test.
Lowe CF, Lawson T, Young M, et al. · J Med Microbiol · 2024
Other devices of this type
Also filed under product code QLX.
- Alinity m EBV (09N43-095)Abbott Molecular, Inc. · 510(k) 2025
- cobas EBV, cobas EBV/BKV Control Kit, cobas Buffer Negative Control KitRoche Molecular Systems, Inc. · De Novo 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.